Is it possible to get lung cancer treatment in Cuba?
On today’s date, the Food and Drug Administration (FDA) authorized CIMAVax for use in clinical studies at Roswell Park, with the first study slated to begin in less than three months.
According to certain research, CIMAvax can help individuals with non-small cell lung cancer live longer lives longer lives. According to the results of one clinical research, long-term treatment of CIMAvax was “very safe.” CIMAvax is not accessible in Canada, according to Health Canada, because no application has been made for the vaccine’s licensure in this country yet.
Roswell and Cuba’s Center for Molecular Immunology, which created the vaccine, began working together in 2011, several years before the Obama administration began loosening its sanctions against the island nation.
CIMAvax works by modulating the patient’s immune response to prevent EGF from being produced. CIMAvax has a “carrier protein” that stimulates the immune system to develop antibodies against the EGF protein, which may then be neutralized. This reduces the amount of circulating EGF in the blood, depriving cancer cells of a critical factor in their development and proliferation.
It has been proposed that CimaVax may also be beneficial in treating other forms of cancer that are dependent on EGF/EGFR, such as prostate cancer, which accounts for a large proportion of cases.
Patients treated with TarcevaTM experienced an overall anti-cancer response rate of 9 percent, with an average duration of response of nearly 8 months in the study population. TarcevaTM was shown to be effective in stabilizing disease in 35% of patients, whereas it was found to be ineffective in accelerating cancer development in 38% of patients.
Pembrolizumab is the active ingredient in Keytruda. It is a member of a family of medications known as PD-1 inhibitors. With Keytruda, your immune system is instructed to target cancer cells in a manner similar to that of an immunotherapy medicine. Keytruda is administered by healthcare professionals through an intravenous (IV) infusion.
Non-small cell lung cancer therapy with Vaxira® is possible. Vaxira® is a therapeutic vaccination (NSCLC). It is made up of the antigen Racotumomab and the adjuvant aluminum hydroxide.
Colostrum and human milk both include peptides that are known as epidermal growth factors (EGFs).
Nicuzumab was discovered at the Center of Molecular Immunology (CIM) in Cuba and co-developed by the Canadian company YM Biosciences (now a division of the American pharmaceutical company Eli Lilly & Company).